CARMEL, Ind., March 4, 2025 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that it will report financial results for its fourth quarter and full year 2024 ended December 31, 2024, on Tuesday, March 11, 2025, before the market opens. The company will host a conference call that same day, March 11, 2025, at 9:00 a.m. ET, to discuss the results.
Interested parties can access the conference call via webcast, available in the investors section of the company's website at https://ir.syrahealth.com/presentations/q4-and-full-year-2024-earnings-call.
Investors who would like to submit a question to be addressed on the call should email This email address is being protected from spambots. You need JavaScript enabled to view it..
A webcast replay will be available in the investors section of the company's website at https://ir.syrahealth.com/presentations/q4-and-full-year-2024-earnings-call.
About Syra Health
Syra Health is a healthcare technology company powering better health in critical areas such as behavioral and mental health, population health, and the healthcare workforce. The company's leading-edge technology products and innovative services focus on prevention, access, and affordability. With a commitment to improving health, Syra Health is advancing healthcare solutions nationwide and around the world. For more information, please visit www.syrahealth.com.
Contacts
For Investor Inquiries:
Corbin Woodhull
Managing Director, Global Advisory
Hayden IR
602-476-1821
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Media Inquiries:
Christine Drury
Director of Corporate Communications
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.06 |
Daily Change: | -0.006 -8.96 |
Daily Volume: | 97,123 |
Market Cap: | US$692K |
February 18, 2025 December 02, 2024 November 26, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load